A5103183042- Cholangiocarcinoma and Gallbladder Cancer Studies
- Fibroblast Growth Factor Research
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Transplantation: Methods and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Metastasis and carcinoma case studies
- Gallbladder and Bile Duct Disorders
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Hormonal and reproductive studies
- Estrogen and related hormone effects
- Heavy Metal Exposure and Toxicity
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Extracellular vesicles in disease
- Nanoplatforms for cancer theranostics
Ronald Reagan UCLA Medical Center
2016-2024
UCLA Medical Center
2016-2024
University of Guilan
2024
University of California, Los Angeles
2011-2023
UCLA Health
2014-2022
APLA Health
2021
Mashhad University of Medical Sciences
2017-2020
UCLA Jonsson Comprehensive Cancer Center
2018
Memorial Sloan Kettering Cancer Center
2017
The University of Texas MD Anderson Cancer Center
2017
Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking 2 (HER2), to aromatase letrozole as first-line treatment (HR) -positive metastatic cancer (MBC).Postmenopausal women with HR-positive MBC were randomly assigned daily (2.5 mg orally) plus lapatinib (1,500 or placebo. The primary end point was progression-free...
Purpose No standard treatment exists for patients with cholangiocarcinoma whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors FGFR alterations. Methods A multicenter, open-label, phase II study ClinicalTrials.gov identifier: NCT02150967)...
Abstract We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier creates more opportunities curative therapeutic interventions. EVs are present in circulation at relatively stages disease, providing potential detection. develop an EV (i.e., Click Chips) synergistically integrating chemistry-mediated capture/release, multimarker antibody...
Purpose Anthracyclines, taxanes, and alkylating agents are among the most active in treatment of adjuvant breast cancer (BC), but optimal schedule for their administration is unknown. We performed an trial to compare sequential regimen doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) combination TAC. Patients Methods Women node-positive, human epidermal growth factor receptor 2–nonamplified, operable BC were stratified number axillary nodes hormone status randomly...
265 Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited. Fibroblast growth factor receptor 2 ( FGFR2) gene fusions occur in 13–17% of intrahepatic CCA. A single-arm, phase II study (NCT02150967) evaluated infigratinib, an ATP-competitive FGFR1–3-selective oral tyrosine kinase inhibitor, previously-treated advanced CCA with FGFR fusions/rearrangements. Methods: Adult patients advanced/metastatic ≥1 line systemic...
Hepatocellular carcinoma (HCC) is a leading cause of mortality. Checkpoint inhibitors programmed cell death protein‐1 (PD‐1) and death‐ligand 1 (PD‐L1) have shown great efficacy, but lack biomarkers that predict response. Circulating tumor cells (CTCs) promise as liquid‐biopsy biomarker; however, data on HCC CTCs expressing PD‐L1 not been reported. We sought to detect PD‐L1‐expressing HCC‐CTCs investigated their role prognostic predictive biomarker. Using an antibody‐based platform, were...
Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib oral 1-3 kinase inhibitor. Favorable results from a Phase II trial infigratinib in advanced/metastatic FGFR-altered has led to its further investigation the front-line setting. In this article we describe design, objectives and rationale for PROOF 301, III multicenter, open label, randomized comparison standard care...
The sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers early cancer detection. In this study, we aim to develop an HCC EV-based surface protein assay detection HCC.Tissue microarray was used evaluate four potential HCC-associated markers. An EV assay, composed covalent chemistry-mediated purification and real-time immuno-polymerase chain reaction readouts,...
Current clinicopathologic staging systems and serum biomarkers poorly discriminate tumor biology in hepatocellular carcinoma (HCC), with high recurrence rates following curative‐intent surgical resection liver transplantation (LT). Identification of accurate for improved prognostication treatment selection is a critical unmet need. We sought to develop novel “liquid‐biopsy” assay capable detecting HCC circulating cells (CTCs) characterizing phenotypic subpopulations prognostic significance....
335 Background: CCA is a hepatobiliary malignancy with poor prognosis and few treatment options following cytotoxic therapy in the first-line metastatic setting. The fibroblast growth factor receptor (FGFR) axis may promote tumorigenesis. FGFR2 fusions (in up to 17% of intrahepatic CCAs) predict FGFR inhibitor sensitivity. A prior phase 1 trial selective pan-FGFR BGJ398 showed antitumor activity pt harboring an fusion. Methods: This ongoing 2, open-label study evaluating oral 125 mg once...
We report single-institution clinical efficacy and safety outcomes for patients with unresectable locally advanced cholangiocarcinoma who were treated stereotactic body radiation therapy (SBRT) a subset of received neoadjuvant SBRT chemotherapy as part an orthotopic liver transplantation (OLT) protocol.From October 2008 to June 2015, 31 consecutive extrahepatic (n = 25) or intrahepatic 6) retrospectively analyzed. Four underwent transplantation, 1 resection. was delivered in 5 fractions...
An oligocationic peptide compound (ALX40-4C) was developed for consideration in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This designed to mimic basic domain HIV-1 transactivation protein, Tat, and will competitively inhibit Tat binding its specific RNA hairpin target (TAR [transactivation region]), found at 5' end all transcripts. Blocking Tat-TAR interactions can abrogate replication. ALX40-4C shown replication HIV-1NL4-3 a range cell types, including primary...
Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 PatientsAntoinette S. Gomes1, Phillip A. Monteleone1, James W. Sayre2, Richard Finn3, Saeed Sadeghi3, Myron J. Tong4, Carolyn D. Britten5 and Ronald Busuttil4Audio Available | Share
The objective of this article is to evaluate the utility preoperative needle biopsy (PNB) grading hepatocellular carcinoma (HCC) as a biomarker for liver transplantation (LT) candidate selection. Given prognostic significance HCC tumor grade, PNB has been proposed LT Clinicopathologic characteristics recipients (1989-2014) with were analyzed, and concordance grade explant vascular invasion was assessed determine whether incorporation accepted transplant criteria improved Of 965 patients...
The HER-2/neu gene product is a 185 kDa Type I receptor tyrosine kinase which consists of an extracellular domain, transmembrane and cytoplasmic tail. initial discovery that amplification subsequent overexpression the oncogene plays pivotal role in pathogenesis 20%–25% breast cancers has since led to significant clinical advances management this subtype cancer. first approved HER2-targeted therapy, trastuzumab, humanized monoclonal antibody against domain HER2 demonstrated survival benefits...
Abstract Somatic copy number alterations (SCNAs) are important genetic drivers of many cancers. We investigated the feasibility obtaining SCNA profiles from circulating tumor cells (CTCs) as a molecular liquid biopsy for hepatocellular carcinoma (HCC). CTCs ten HCC patients underwent profiling. The Cancer Genome Atlas (TCGA) data were used to develop cancer origin classification model, which was then evaluated classifying 44 multiple types. Sequencing 18 CTC samples (median: 4 CTCs/sample)...
Background: Fibroblast growth factor receptor 2 (FGFR2) fusions occur in 13–17% of intrahepatic cholangiocarcinomas (IHC). A multicenter, open-label, phase II study (NCT02150967) evaluated the antitumor activity infigratinib, an ATP-competitive FGFR1–3-selective oral tyrosine kinase inhibitor, patients (pts) with previously-treated advanced IHC containing FGFR2 fusions. Methods: Pts received infigratinib 125 mg orally daily for 21 days 28-day cycles until unacceptable toxicity, disease...